Modern aspects of nonalcoholic fatty liver disease patients treatment

Дичева, Д. Т.; Кузнецова, Е. И.

doi:10.26442/2075-1753_2018.8.20-23

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Основываясь на данных крупного исследования, включающего анализ 7 800 441 выписного эпикриза, среди которых 32 347 (0,4%) и 271 049 (3,5%) включали диагноз НАЖБП и другие хронические заболевания печени, соответственно, выявлено, что НАЖБП в 3,5 раза чаще ассоциирована с ЖКБ, нежели другие заболевания желудочно-кишечного тракта [17]. Аналогичными являются данные, описанные отечественными специалистами, указывающие, что третья часть пациентов с НАЖБП на момент обследования имеют ЖКБ [18]. Метаанализ 12 наблюдательных исследований с включением 76 629 пациентов продемонстрировал, что у пациентов с НАЖБП риск возникновения ЖКБ больше в 1,5 раза [12].…”

Section: ââåäåíèåunclassified

Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease

Cherkashchenko¹,

Livzan

Кролевец

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To determine the diagnostic value of clinical features of the comorbid course of non-alcoholic fatty liver disease (NAFLD) and gallstone disease (GD) to improve the effectiveness of patient management. Materials and methods. 183 patients with NAFLD were included into the open comparative study. The main group was represented by patients with NAFLD and GD (n=88), of which 53 patients underwent cholecystectomy (CE). The comparison group was represented by patients with NAFLD without GD (n=95). A standard laboratory and instrumental examinations were performed, including elastometry to assess of the stage of liver fibrosis. Results. There were more women in the main group (2=8.48; p0.01). There were positive correlations between the age of patients and the duration of NAFLD with the presence of GD and CE (rs=0.135; p0.01 and rs=0.168; p0.01 respectively). Patients of the main group had the general weakness and fatigue (2=11.33, rs=0.234; p0.01 and 2=15.68, rs=0.281; p0.01 respectively), as well as a bitter taste in the mouth (2=11.66; p0.01; rs=0.147; p0.01). Coronary heart disease was diagnosed more often among people suffering from NAFLD and GD (25% vs 9.47% in patients of the comparison group, p0.01). Both of NAFLD and GD were associated with the development of type 2 diabetes (rs=0.164; p0.01). Individuals suffering from GD after CE had higher LDL and GGT values (rs=0.228; p0.01 and rs=0.298; p0.01 respectively). The number of people with advanced fibrosis were significantly higher (26.31%) in the GD group, especially among people after CE (30.18%). The stage of liver fibrosis had a positive significant relationship with CE (rs=0.366; p0.01). Conclusion. Patients suffering from GD and NAFLD had a symptom of dyspepsia and general weakness. High prevalence of type 2 diabetes and сoronary heart disease, high level of LDL and GGT were found in patients with GD and after CE. CE in patients suffering from GD and NAFLD was associated with the formation of progressive stages of liver fibrosis.

show abstract

Section: ââåäåíèåunclassified

Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease

Cherkashchenko¹,

Livzan

Кролевец

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…Результаты крупного исследования, включающего анализ 7 800 441 выписного эпикриза, среди которых в 32 347 (0,4%) и 271 049 (3,5%) случаях установлен диагноз НАЖБП и хронические заболевания печени, соответственно, демонстрируют, что в 3,5 раза чаще отмечено именно сочетание НАЖБП и ЖКБ, нежели других заболеваний желудочно-кишечного тракта (ЖКТ) [4]. Отечественные ученые демонстрируют, что треть пациентов с НАЖБП на момент обследования имеют ЖКБ [5].…”

unclassified

Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease

Cherkashchenko

Livzan

Кролевец

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim.To update information about comorbidity of non-alcoholic fatty liver disease (NAFLD) and gallstones disease (GD), evaluation of clinical and laboratory data, including insulin, leptin and adiponectin in individuals with NAFLD in combination with GD. Materials and methods.According to the design, we conducted an open comparative study of 169 patients with NAFLD. The following comparison groups were formed: group 1 (n=95) patients with NAFLD without GD, group 2 (n=35) patients with NAFLD and GD and group 3 (n=39) patients with NAFLD, GD and previous cholecystectomy. Results.A high prevalence of coronary heart disease was found in the group of patients with GD and cholecystectomy (2=6.198,p0.05); positive, statistically significant correlation relationships of cholelithiasis, cholecystectomy with ischemic heart disease (rs=0.172,p0.05 andrs=0.241,p0.05, respectively). There was a statistically significant decrease in total bilirubin and total protein in patients of group 3 (H=7.376,p0.03 and H=6.345,p0.04). The level of leptin is statistically significantly higher and positively interrelated with cholecystectomy (H=5.812,p0.05,rs=0.313,p0.05). Conclusion.Patients with NAFLD, GD and previous cholecystectomy have a high prevalence of coronary heart disease; the phenomenon of insulin and leptin resistance, high level of adiponectin were revealed in patients with NAFLD and gallstones; hyperleptinemia was observed among patients with NAFLD, GD after cholecystectomy.

show abstract

Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease

Ефремова

Chernobay

Pogurelskaya³

2021

Sibirskij nauchnyj medicinskij zhurnal

View full text Add to dashboard Cite

A number of studies have now been conducted confirming the relationship between arterial hypertension (AH) and nonalcoholic fatty liver disease (NAFLD). It has been proved that the presence of AH increases or provokes the development of NAFLD. A study of telmisartan effectiveness in combination with atorvastatin and ursodeoxycholic acid (UDCA) in patients with AH and NAFLD was carried out in this article. Material and methods. The study included 39 patients diagnosed with arterial hypertension in combination with NAFLD, who were treated with a combination of drugs: Telmisartan, Atorvastatin and UDCA for 12 weeks. The comparison group consisted of 33 patients with NAFLD who received basic NAFLD therapy without telmisartan and atorvastatin. The study analyzed the efficacy of the prescription of this combination on the clinical condition of patients with AH combined with NAFLD, their hemodynamic parameters, the levels of blood lipid spectrum, IL-6, leptin, adiponectin, and the dynamics of echocardiographic and ultrasonographic parameters. Results and discussion. It has been revealed, that application of telmisartan, atorvastatin and UZHK combination for 12 weeks significantly reduced BP levels to the target values, improved hemodynamic indexes, led to reduction of atherogenic components of blood lipid spectrum. And also prescription of this combination decreased IL-6 and leptin levels, increased adiponectin content, which contributed to improvement of the general state of patients, decrease in the severity of clinical and functional manifestations of NAFLD.

show abstract

Modern aspects of nonalcoholic fatty liver disease patients treatment

Cited by 5 publications

References 0 publications

Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease

Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease

Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease

Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease

Contact Info

Product

Resources

About